Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.
During the past few years, several genetic aberrations that may contribute to increased risks for development of breast and/or ovarian cancers have been identified. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian focus specifically on the assessment of genetic mutations in BRCA1/BRCA2, TP53, and PTEN, and recommend approaches to genetic testing/counseling and management strategies in individuals with these mutations. This portion of the NCCN Guidelines includes recommendations regarding diagnostic criteria and management of patients with Cowden Syndrome/PTEN hamartoma tumor syndrome.
Daly, MB; Pilarski, R; Axilbund, JE; Buys, SS; Crawford, B; Friedman, S; Garber, JE; Horton, C; Kaklamani, V; Klein, C; Kohlmann, W; Kurian, A; Litton, J; Madlensky, L; Marcom, PK; Merajver, SD; Offit, K; Pal, T; Pasche, B; Reiser, G; Shannon, KM; Swisher, E; Voian, NC; Weitzel, JN; Whelan, A; Wiesner, GL; Dwyer, MA; Kumar, R; National comprehensive cancer network,
Volume / Issue
Start / End Page
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)